| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/16/2001 | EP1098639A1 Use of a glucose uptake enhancer for reducing apoptosis |
| 05/16/2001 | EP1098638A1 Use of a glucose uptake enhancer for reducing post-ischemic injury of the heart |
| 05/16/2001 | EP1098631A1 Pharmaceutical composition in particular for preventing and treating mucositis induced by radiotherapy or chemotherapy |
| 05/16/2001 | EP1098626A2 Method for regulating hair growth |
| 05/16/2001 | EP1011673B1 Novel niddm regimen |
| 05/16/2001 | EP0941089B1 Use of anti-microtubule agents for treating or preventing multiple sclerosis |
| 05/16/2001 | CN1295677A Methods and apparatus for accelerated orthokeratology |
| 05/16/2001 | CN1295578A Pharmaceuticals for imaging of angiogenic disorders |
| 05/16/2001 | CN1295482A Antagonists of the inflammatory mediator oncostatin M (OSM) |
| 05/16/2001 | CN1295479A Beta 2-adrenergic receptor agonist |
| 05/16/2001 | CN1295456A Acidified composition for topical treatment of nail and skin conditions |
| 05/16/2001 | CN1065744C Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor |
| 05/15/2001 | US6232460 Isolated nucleic acid molecule which encodes an SCP-1 mutein |
| 05/15/2001 | US6232459 Synaptojanin isoform |
| 05/15/2001 | US6232454 Nucleic acid and amino acid sequences and use in diagnosis, treatment, and prevention of cancer and immune disorders |
| 05/15/2001 | US6232443 Useful markers in diagnosing and monitoring cancerous renal cells; detecting cell proliferative disorders |
| 05/15/2001 | US6232441 PIGR-1, a member of immunoglobulin gene superfamily |
| 05/15/2001 | US6232350 Administering triphenylethylene antiestrogens (tamoxifen and derivatives-neuroprotectants) to act as cell-nucleus receptor blockers |
| 05/15/2001 | US6232330 Therapeutically effective amount of an insulin sensitivity enhancer(pioglitazone,troglitazone and salts) in combination with an aldose reductase inhibitor(tolurestat,epalrestat,imirestat,zenarestat) |
| 05/15/2001 | US6232328 Non-systemic control of parasites |
| 05/15/2001 | US6232326 Treatment for schizophrenia and other dopamine system dysfunctions |
| 05/15/2001 | US6232321 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| 05/15/2001 | US6232315 Method for treating inflammatory diseases by administering a thrombin inhibitor |
| 05/15/2001 | US6232308 Useful for inhibiting bone resorption, treating and preventing osteoporosis, inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, and angiogenesis |
| 05/15/2001 | US6232300 Administering as hepatitis b viricide |
| 05/15/2001 | US6232299 Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
| 05/15/2001 | US6232298 Administering uridine, cytidine, or orotic acid or salt or acylated derivative to treat cachexia |
| 05/15/2001 | US6232295 Cell-specific contrast agent and gene delivery vehicles |
| 05/15/2001 | US6232289 Method of treating interstitial cytitis with recombinant heparin-binding epidermal growth factor-like growth factor (HB-EGF) |
| 05/15/2001 | US6232097 Nucleotide sequences coding enzymatic polypeptide; prevent bacterial infection; wound healing agents; for vaccine development |
| 05/15/2001 | US6232082 Vaccines |
| 05/15/2001 | US6232077 Genetic engineering and expression; cancer diagnosis |
| 05/15/2001 | US6232071 Tenascin-C nucleic acid ligands |
| 05/15/2001 | US6232064 Fibrosis and atherosclerosis determination |
| 05/15/2001 | US6231889 Unit dosage forms for the treatment of herpes simplex |
| 05/15/2001 | US6231875 Acidified composition for topical treatment of nail and skin conditions |
| 05/15/2001 | US6231874 Moisturizers |
| 05/15/2001 | US6231851 Methods and compositions for the dry powder formulation of interferons |
| 05/15/2001 | US6231848 N-vinyllactam homo or copolymer complexed with hydrogen peroxide and colloidal silver or silver salt useful as prophylaxis agent |
| 05/15/2001 | US6231594 Method of controlling body temperature while reducing shivering |
| 05/15/2001 | US6231536 Method and compositions for treatments of cancers |
| 05/15/2001 | CA2238978C Retroviral protease inhibiting compounds |
| 05/15/2001 | CA2158054C Conjugates of proteins and bifunctional ligands |
| 05/10/2001 | WO2001033223A1 Composite nanospheres and their conjugates with biomolecules |
| 05/10/2001 | WO2001033221A1 Axor35, a g-protein coupled receptor |
| 05/10/2001 | WO2001033218A1 Method for identifying active anti-apoptosis compounds |
| 05/10/2001 | WO2001032926A2 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 05/10/2001 | WO2001032925A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 05/10/2001 | WO2001032893A1 Recombinant therapeutic fusion proteins |
| 05/10/2001 | WO2001032888A2 Human transferase molecules |
| 05/10/2001 | WO2001032878A2 A novel polypeptide hormone phosphatonin |
| 05/10/2001 | WO2001032877A2 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 05/10/2001 | WO2001032864A2 Gpcr-kd5 polypeptides and dna sequences thereof |
| 05/10/2001 | WO2001032831A2 Screening and use of agents which block or activate intein splicing utilizing natural or homologous exteins |
| 05/10/2001 | WO2001032706A2 Novel human transporter proteins and polynucleotides encoding the same |
| 05/10/2001 | WO2001032704A1 Choline transporter like (ctl) membrane proteins involved in choline transport |
| 05/10/2001 | WO2001032696A2 Traf family proteins |
| 05/10/2001 | WO2001032695A2 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF |
| 05/10/2001 | WO2001032687A1 10 human secreted proteins |
| 05/10/2001 | WO2001032675A1 32 human secreted proteins |
| 05/10/2001 | WO2001032674A1 26 human secreted proteins |
| 05/10/2001 | WO2001032638A1 Indeno-, naphtho-, and benzocyclohepta-dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments |
| 05/10/2001 | WO2001032624A1 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| 05/10/2001 | WO2001032622A1 Positive modulators of nicotinic receptor agonists |
| 05/10/2001 | WO2001032620A1 Positive modulators of nicotinic receptor agonists |
| 05/10/2001 | WO2001032619A1 Positive modulators of nicotinic receptor agonists |
| 05/10/2001 | WO2001032606A1 Compounds having mif antagonist activity |
| 05/10/2001 | WO2001032596A1 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001032263A1 Use of dopamine-d3 receptor agonists for the therapy of salt-dependent hypertension |
| 05/10/2001 | WO2001032232A2 Method of forming micropores in skin |
| 05/10/2001 | WO2001032216A2 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | WO2001032215A1 Antiviral agent for use in treatment of cancer |
| 05/10/2001 | WO2001032209A1 A novel method of diagnosing, monitoring, staging, imaging and treating cancer |
| 05/10/2001 | WO2001032202A1 Use of nitric oxide for the treatment of airway constriction |
| 05/10/2001 | WO2001032200A1 Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety |
| 05/10/2001 | WO2001032198A1 Prevention and treatment of biomaterial-associated infections |
| 05/10/2001 | WO2001032188A1 Compositions of orally administered nutritional supplements to repair articular cartilage |
| 05/10/2001 | WO2001032186A2 Inhibitors of the inositol polyphosphate 5-phosphatase ship2 molecule |
| 05/10/2001 | WO2001032180A2 Composition for treatment of constipation and irritable bowel syndrome |
| 05/10/2001 | WO2001032168A1 Method of treating benign forgetfulness |
| 05/10/2001 | WO2001032167A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 05/10/2001 | WO2001032165A1 Method for administering a phosphodiesterase 4 inhibitor |
| 05/10/2001 | WO2001032161A2 Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |
| 05/10/2001 | WO2001032158A2 Pharmaceutical composition comprising a combination of metformin and another antidiabetic agent |
| 05/10/2001 | WO2001032157A2 Pharmaceutical composition comprising a combination of metformin and glibenclamide |
| 05/10/2001 | WO2001032156A2 Methods for treating fibroproliferative diseases |
| 05/10/2001 | WO2001032155A2 Use of egfr tyrosine kinase inhibitors for treating breast cancer |
| 05/10/2001 | WO2001032154A2 Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation |
| 05/10/2001 | WO2001032153A2 Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| 05/10/2001 | WO2001032149A1 Osmotic controlled release drug delivery device |
| 05/10/2001 | WO2001032145A1 Method of cancer treatment |
| 05/10/2001 | WO2001032144A1 Dry powder compositions having improved dispersivity |
| 05/10/2001 | WO2001032137A1 Slimming composition containing a substance inducing il-6 production |
| 05/10/2001 | WO2001032130A2 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001032127A2 Method and compositions for treating pulmonary diseases |
| 05/10/2001 | WO2001032115A1 Transdermal administration of huperzine |
| 05/10/2001 | WO2001032070A2 Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| 05/10/2001 | WO2001032038A1 Fibrous-liponutritional complexes and compositions containing them |
| 05/10/2001 | WO2001032029A2 Compositions comprising edible oils or fats and phytosterols and/or phytostanols substantially dissolved therein |
| 05/10/2001 | WO2001019378A3 Solid lipid formulations comprising an inhibitor of lipases and a fatty acid ester of polyols |